Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE (ABBV)

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/22/2017 06/23/2017 06/26/2017 06/27/2017 06/28/2017 Date
73.18(c) 72.64(c) 72.74(c) 72.39(c) 72.92(c) Last
9 998 906 7 064 455 4 019 452 4 490 570 4 196 191 Volume
+2.58% -0.74% +0.14% -0.48% +0.73% Change
More quotes
Financials ($)
Sales 2017 27 752 M
EBIT 2017 11 850 M
Net income 2017 7 256 M
Debt 2017 26 432 M
Yield 2017 3,54%
Sales 2018 30 378 M
EBIT 2018 13 750 M
Net income 2018 8 709 M
Debt 2018 22 650 M
Yield 2018 3,91%
P/E ratio 2017 15,14
P/E ratio 2018 12,78
EV / Sales2017 5,13x
EV / Sales2018 4,57x
Capitalization 116 055 M
More Financials
Company
AbbVie, Inc. is a research-based biopharmaceutical company.It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products.The company focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and... 
Sector
Pharmaceuticals
Calendar
07/12Ex-dividend day
More about the company
Surperformance© ratings of AbbVie
Trading Rating : Investor Rating :
More Ratings
Latest news on ABBVIE
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23 ABBVIE : Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrenta..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
06/23 ABBVIE : Announces Pivotal Phase 2 Trial Evaluating VENCLYXTO™ (venetoclax..
06/22 ABBVIE : Declares Quarterly Dividend
06/22 ABBVIE : New Findings Reported from AbbVie Describe Advances in Pre-Trial Resear..
06/22 United States Anesthesia Drugs Market & Forecast
06/17 ABBVIE : Sen. Nan Orrock, Rep. Keisha Waites to Partner in Volunteer Project
06/16 ABBVIE : a Top Socially Responsible Dividend Stock With 3.6% Yield (ABBV)
06/15 STUDIES CONDUCTED AT ABBVIE ON PHARM : The modernization of the...
More news
Sector news : Specialty & Advanced Pharmaceuticals
09:22a COVESTRO : vows to cash out to shareholders if no takeover on cards
04:55a MYLAN : Investors call on Mylan chairman, director to step down
06/28 UK blue chips led lower by Hargreaves as strong pound takes toll
06/28DJVECTURA : In Asthma Collaboration With Novartis's Sandoz
06/28DJGLAXOSMITHKLINE : Announces US Filing For Mepolizumab
More sector news : Specialty & Advanced Pharmaceuticals
4-Traders Strategies on ABBVIE 
2015A likely recovery
More Strategies
Latest Tweets
06/28Failed in its 1st try to win approval of a biosimilar, $CHRS cuts 51 jobs  
06/28Failed in its 1st try to win approval of a biosimilar, $CHRS cuts 51 jobs  
06/28Global Anti-inflammatory Therapeutics Market 2017-2021: Emergence of Novel An.. 
06/28Buy AbbVie For The Pipeline  
06/27$ABBV - Long setup -
1
More tweets
Qtime:164
News from SeekingAlpha
06/28 Buy AbbVie For The Pipeline
06/26 Recent Stock Purchase June 2017
06/25 3 THINGS IN BIOTECH YOU SHOULD LEARN : June 25, 2017
06/23 European Ad Comm backs AbbVie's G/P eight-week HCV combo pill
06/23 Buy Hasbro At $110 - Cramer's Lightning Round (6/22/17)
Advertisement
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | ABBV | US00287Y1091 | 4-Traders
Full-screen chart
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 74,2 $
Spread / Average Target 1,8%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Azita Saleki-Gerhardt Senior Vice President-Operations
William J. Chase Chief Financial Officer & Executive Vice President
Michael E. Severino Chief Scientific Officer & Executive VP
Robert J. Alpern Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE16.45%116 055
MERCK KGAA9.08%16 374
KYOWA HAKKO KIRIN CO L..29.85%10 788
JAZZ PHARMACEUTICALS P..42.33%9 325
CONVATEC GROUP38.52%8 102
ZHANGZHOU PIENTZEHUANG..31.91%5 256
More Results